Literature DB >> 7461466

Chemical composition of gallstones resistant to dissolution therapy with chenodeoxycholic acid.

M J Whiting, V Jarvinen, J M Watts.   

Abstract

The gallstones of 14 patients, who had been treated unsuccessfully with chenodeoxycholic acid (15 mg/kg/day) for at lest six months, were obtained at cholecystectomy. The stones were then analysed for their cholesterol and calcium content. Two patients' stones were black in colour and low in cholesterol content, and were classified as pigment stones. Of the remaining 12 patients' stones, which all contained more than 70% cholesterol, 10 contained at lest 1% calcium on the stone surface. In two patients, the surface contained sufficient calcium to form a radio-opaque layer, although the stones had been radiolucent at the start of dissolution therapy. Overall, the results suggest that deposition of calcium salts inhibits the dissolution treatment of gallstones with chenodeoxycholic acid, irrespective of the radiolucency of the stones.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7461466      PMCID: PMC1419403          DOI: 10.1136/gut.21.12.1077

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  The value of radiology in predicting gallstone type when selecting patients for medical treatment.

Authors:  G D Bell; R H Dowling; B Whitney; D J Sutor
Journal:  Gut       Date:  1975-05       Impact factor: 23.059

Review 2.  Pigment gallstones.

Authors:  R D Soloway; B W Trotman; J D Ostrow
Journal:  Gastroenterology       Date:  1977-01       Impact factor: 22.682

3.  Efficacy and specificity of chenodeoxycholic acid therapy for dissolving gallstones.

Authors:  J L Thistle; A F Hofmann
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

4.  Letter: A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates.

Authors:  P J Thomas; A F Hofmann
Journal:  Gastroenterology       Date:  1973-10       Impact factor: 22.682

5.  Evaluation of radiographic lucency or opaqueness of gallstones as a means of identifying cholesterol or pigment stones. Correlation of lucency or opaqueness with calcium and mineral.

Authors:  B W Trotman; E J Petrella; R D Soloway; H M Sanchez; T A Morris; W T Miller
Journal:  Gastroenterology       Date:  1975-06       Impact factor: 22.682

6.  Factors influencing human gallstone dissolution in monkey, dog, and human bile.

Authors:  G D Bell; D J Sutor; B Whitney; R Dowling
Journal:  Gut       Date:  1972-10       Impact factor: 23.059

7.  Chenodeoxycholic acid treatment of gallstones. A follow-up report and analysis of factors influencing response to therapy.

Authors:  J H Iser; H Dowling; H Y Mok; G D Bell
Journal:  N Engl J Med       Date:  1975-08-21       Impact factor: 91.245

8.  The medical treatment of cholesterol gallstones: experience with chenodeoxycholic acid.

Authors:  L Barbara; E Roda; A Roda; C Sama; D Festi; G Mazzella; R Aldini
Journal:  Digestion       Date:  1976       Impact factor: 3.216

9.  [Selection of patients with gallstones for litholysis (author's transl)].

Authors:  C Wolpers
Journal:  Leber Magen Darm       Date:  1976

10.  Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man.

Authors:  R T Holzbach; M Marsh; M Olszewski; K Holan
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

View more
  12 in total

1.  The effects of dietary phospholipids enriched with phosphatidylethanolamine on bile and red cell membrane lipids in humans.

Authors:  R Pakula; F M Konikoff; M Rubin; Y Ringel; Y Peled; A Tietz; T Gilat
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

2.  Measurement of calcium content of gallstones by computed tomography and the relationship between gallbladder function and calcification of gallstones.

Authors:  M Yoneda; N Tamasawa; I Makino; K Takebe; K Sakuraba; T Tamura
Journal:  Gastroenterol Jpn       Date:  1990-08

3.  Computed tomography in predicting gall stone solubility: a prospective trial.

Authors:  A Caroli; G Del Favero; F Di Mario; F Spigariol; P Scalon; T Meggiato; C Zambelli; R Naccarato
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

4.  Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse.

Authors:  S P Pereira; M J Veysey; C Kennedy; S H Hussaini; G M Murphy; R H Dowling
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

5.  Duodenal bile examination in identifying potential non-responders to bile salt treatment and its comparison with gall bladder bile examination.

Authors:  D K Agarwal; G Choudhuri; V A Saraswat; T S Negi; V K Kapoor; R Saxena
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  Retrospective comparison of 'Cheno' and 'Urso' in the medical treatment of gallstones.

Authors:  T J Meredith; G V Williams; P N Maton; G M Murphy; H M Saxton; R H Dowling
Journal:  Gut       Date:  1982-05       Impact factor: 23.059

7.  Prospective, multicenter study on value of computerized tomography (CT) in gallstone disease in predicting response to bile acid therapy.

Authors:  M L Petroni; R P Jazrawi; A Grundy; A Lanzini; M G Pigozzi; A Biasio; K W Heaton; J Virjee; T C Northfield
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

8.  Natural history and treatment with ursodiol of gallstones formed during rapid loss of weight in man.

Authors:  J W Marks; T Stein; L J Schoenfield
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

9.  Chemical and physical properties of gall stones in South Australia: implications for dissolution treatment.

Authors:  M J Whiting; B M Bradley; J M Watts
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

10.  Effect of laser fragmentation of cholesterol and mixed gallstones on in vitro dissolution in methyl tert-butyl ether.

Authors:  B F Smith
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.